Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Nurix Therapeutics. The associated price target remains the same with $15.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Terence Flynn’s rating is based on several key considerations surrounding Nurix Therapeutics’ current developments and future prospects. The company has shown promising progress with its bexobrutideg (bexdeg) program, particularly in chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM), with data indicating durable and deepening responses. However, the success of these programs is still contingent on further clinical trials and regulatory approvals, which introduces a level of uncertainty.
Additionally, while Nurix’s collaboration with Sanofi on the STAT6 degrader program presents a potential upside, the anticipated filing for an investigational new drug (IND) is not expected until 2026. This timeline suggests that any significant impact on the company’s financials may not materialize in the near term. Given these factors, Flynn’s Hold rating reflects a balanced view of the potential opportunities and risks associated with Nurix’s pipeline and market position.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $22.00 price target.
NRIX’s price has also changed dramatically for the past six months – from $12.540 to $19.550, which is a 55.90% increase.